论文部分内容阅读
目的观察瑞舒伐他汀钙治疗高脂血症的安全性和有效性。方法 92例高脂血症患者采用随机双盲阳性药物平行对照法将患者分为3组:试验A组、试验B组和对照组。试验A组患者服用瑞舒伐他汀钙10 mg/d;试验B组患者服用瑞舒伐他汀钙20 mg/d;对照组患者服用阿托伐他汀钙20 mg/d。分别就胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)改变情况及不良反应情况进行综合比较。结果三组相比,服药8周后,对照组LDL-C(3.79±1.29)mmol/L小于试验A组(2.68±0.69)mmol/L和试验B组(2.89±1.03)mmol/L,差异有统计学意义(P<0.05)。治疗后LDL-C,试验A组32例达标,达标率84.21%;试验B组有22例达标,达标率75.86%;对照组患者中只有10例达标,达标率仅为40.00%。三组患者LDL-C比较,差异有统计学意义(P=0.024)。对照组也低于试验两组,差异有统计学意义(P<0.05)。结论临床使用瑞舒伐他汀钙10~20 mg/d治疗高脂血症,能有效降低LDL-C水平,效果确切、安全。
Objective To observe the safety and efficacy of rosuvastatin calcium in the treatment of hyperlipidemia. Methods Ninety-two patients with hyperlipidemia were divided into three groups by randomized double-blind positive drug parallel control: experimental group A, experimental group B and control group. Patients in trial A received rosuvastatin calcium 10 mg / d; patients in trial group B received rosuvastatin calcium 20 mg / d; patients in control group received atorvastatin calcium 20 mg / d. Cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C) changes and adverse reactions were compared. Results After 8 weeks of treatment, LDL-C (3.79 ± 1.29) mmol / L in control group was less than 2.68 ± 0.69 mmol / L in test group A and 2.89 ± 1.03 mmol / L in test group B There was statistical significance (P <0.05). After treatment, LDL-C, 32 cases in trial group A reached the standard of 84.21%; in trial group B, 22 cases achieved the standard of 75.86%; only 10 cases of the control group achieved the standard of 40.00%. The differences of LDL-C between the three groups were statistically significant (P = 0.024). The control group was also lower than the test two groups, the difference was statistically significant (P <0.05). Conclusion The clinical use of rosuvastatin calcium 10 ~ 20 mg / d treatment of hyperlipidemia, can effectively reduce the level of LDL-C, the effect is accurate and safe.